Home
Health A to Z
News For Medical Professionals
Video
Content Licensing
Custom Content
About
Spanish
Newsletter
Cancer
Molecular residual disease precedes DFS events in patients receiving osimertinib, placebo; most events occur after osimertinib discontinuation or completion
lung cancer
Adobe Stock
By:
Medically Reviewed By:
Farrokh Sohrabi, M.D.
Published on:
Updated on:
Mar 25, 2025, 2:39 pm
Loading content, please wait...
Journal
Surgery
Survival
Prescription Drugs
Lung Cancer
Related Stories
No stories found.